
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
pharmafile | April 1, 2019 | News story | Research and Development, Sales and Marketing | Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of advanced triple-negative breast cancer (TNBC).
The findings showed that the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) delivered an objective response rate (ORR) of 73% in the study’s 26 participants, regardless of tumour biomarker status.
“We are enthusiastic about the potential of this combination in triple-negative breast cancer, an aggressive type of breast cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “These early results support the contribution of ipatasertib to our combination treatment approach in TNBC and reinforce our vision to develop medicines that may benefit patients with this challenging disease.”
Roche confirmed that a multi-centre Phase 3 study into the efficacy of Tecentriq, ipatasertib, and paclitaxel in the treatment of locally advanced/metastatic triple-negative breast cancer will launch later this year.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Roche secures CE Mark for automated latent tuberculosis blood test
Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …






